Skip to main content
SpringerLink
Log in

Gender differences in pharmacokinetics

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The is growing awareness that the underrepresentation of women in clinical trials and in particular in phase I studies may lead to incorrect handling of drugs. Despite the fact that investigations are not performed in a systematic way, there are a number of examples showing pharmacokinetic differences between gender. From the data actually presented, it can be concluded that the activity of CYP 3A4 activity as measured by elimination in vivo is higher in women compared to men. CYP isoenzymes other than CYP 3A4 seem to be more active in men than in woman, as are conjugation reactions, such as glucuronidation.

The influence of changing hormonal levels during the lifetime of a woman has been looked at in some drugs but deserves further systematic investigation. The use of oral contraceptives can interfere with the metabolism of many drugs whereas, in pregnancy, the elimination of antiepileptics is increased which, without dose adjustment, leads to an increased number of seizures. The impacts of hormonal replacement therapy (HRT) on the pharmacokinetics of concomitantly given drugs is an important issue, as HRT is increasingly used, but more research is needed in this field.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fiebach N.H., Viscoli C.M., Horwitz R.I. (1990): Differences between women and man in survival after myocardial infarction: biology or methodology? JAMA, 263, 1092–1096.

    Article  PubMed  CAS  Google Scholar 

  2. Kando J.K., Yonkers K.A., Cole J.O. (1995): Gender as a risk factor for adverse events to medications. Drugs, 50, 1–6.

    Article  PubMed  CAS  Google Scholar 

  3. Swam J.R., Reinstein P.F. (1992): Annual Adverse Drug Experience Report. FDA Report.

  4. Hamilton J.A., Yonkers K.A. (1995): Sex differences in pharmacokinetics of psychotropic medications. Part I: Physiological basis for effects. In: Jensvold, M.J., Halbreich, U., Hamilton, J.A., (Eds) Psychopharmacology of Women: Sex, Gender and Hormonal Considerations. 1st edn, Vol. 1. Washington DC, American Psychiatric Press.

    Google Scholar 

  5. Datz F.L.I., Christian P.E., Moore J. (1987): Gender-related differences in gastric emptying. Nucl. Med., 28, 384–394.

    Google Scholar 

  6. Wald A., Van Thiel D.H., Hoechstetter L., et al. (1981): Gastrointestinal transit: the effect of menstrual cycle. Gastroenterology, 80, 1497–1500.

    PubMed  CAS  Google Scholar 

  7. Horowitz M., Maddern G.J., Chatterton B.E. (1985): The normal menstrual cycle has no effect on gastric emptying. Br J. Obstet. Gynecol., 28, 743–774.

    Google Scholar 

  8. Sweeting J. (1992): Does the time of the month affect the function of the gut? Gastroenterology, 102, 1084–1085.

    PubMed  CAS  Google Scholar 

  9. Aarons L., Hopkins K., Rowland M., et al. (1989): Route of administration and sex differences in the pharmacokinetics of aspirin, administered as its lysine salt. Pharm. Res., 6, 660–666.

    Article  PubMed  CAS  Google Scholar 

  10. Ho P.C., Triggs E.J., Bourn D.W.A., et al. (1985): Effects of age and sex on the disposition of acetylsalicylic acid and its metabolites. Br. J. Clin. Pharmacol., 19, 675–684.

    PubMed  CAS  Google Scholar 

  11. Miaskewicz S.L., Shilvelly C.A., Vesell E.S. (1982): Sex differences in absorption kinetics of sodium salicylate. Clin. Pharmacol. Ther., 31, 30–37.

    Google Scholar 

  12. Jones B.M., Jones M.K. (1976): Alcohol effects in women during the menstrual cycle. Ann. NY Acad. Sci., 273, 576–587.

    Article  PubMed  CAS  Google Scholar 

  13. Verbeeck R.C., Cardinal J.-A., Wallace S.M. (1984): Effect of age and sex on the plasma binding of acidic and basic dugs. Eur. J. Clin. Pharmacol., 27, 91–97.

    PubMed  CAS  Google Scholar 

  14. Wilson K. (1984): Sex-related differences in drug disposition in man. Clin. Pharmacokinet., 9, 189–202.

    Article  PubMed  CAS  Google Scholar 

  15. Routledge P.A., Stargel W.W., Kitchell B.B., et al. (1981): Sex-related differences in the plasma protein binding of lignocaine and diazepam. Br. J. Clin. Pharmacol., 11, 245–250.

    PubMed  CAS  Google Scholar 

  16. Abel S.G., Sellerrs E.M., Naranjo C.A., et al. (1979): Inter-and intra-subject variation in diazepam free fraction. Clin. Pharmacol. Ther. 26, 247–255.

    PubMed  CAS  Google Scholar 

  17. Roberts R.K., Desmond P.V., Wilkinson G.R., et al. (1979): Disposition of chlordiazepoxide: sex differences and effects of oral contraceptives. Clin. Pharmacol. Ther. 25, 826–831.

    PubMed  CAS  Google Scholar 

  18. Kristensen C.B. (1983): Imipramine serum protein binding in healthy subjects. Clin. Pharmacol. Ther., 34, 689–694.

    PubMed  CAS  Google Scholar 

  19. Rowland M., Tozer T.N. (1989): Clinical Pharmacokinetics. Philadelphia, Lea & Febinger.

    Google Scholar 

  20. Holazo A.A., Winkler M.B., Patel I.H. (1988): Effects of gender and oral contraceptives on intramuscular midazolam pharmacokinetics. J. Clin. Pharmacol., 28, 10040–1045.

    Google Scholar 

  21. Greenblatt D.J., Abernethy D.R., Locniskar A., et al. (1984): Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology, 61, 27–36.

    PubMed  CAS  Google Scholar 

  22. Jochemsen R., Van der Graf M., Boeijinga J.K., et al. (1982): Influence of sex, menstrual cycle, and oral contraceptives on the disposition of nitrazepam. Br. J. Clin. Pharmacol., 13, 319–324.

    PubMed  CAS  Google Scholar 

  23. Kietzman D., Briede I., Bouillon T., Michaelis H.C., Gundert-Remy U., Kettler D. (1996): Pharmacokinetics of piritramide after intravenous bolus injection in surgical patients. Acta Anaesthesiol. Scand., In press.

  24. Nafziger A.N., Bertino Jr J.S. (1989): Sex-related differences in theophylline pharmacokinetics. Eur. J. Clin. Pharmacol., 37, 97–100.

    PubMed  CAS  Google Scholar 

  25. Cuzzoli L., Schinella M., Tellini U. (1990): The effect of sex and cardiac failure on the pharmacokinetics of a slow-release theophylline formulation in the elderly. Pharmacol. Res., 22, 137–138.

    Article  Google Scholar 

  26. Jennings T.S., Nafziger A.N., Davidson L., et al. (1993): Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. J. Lab. Clin. Med., 122, 208–216.

    PubMed  CAS  Google Scholar 

  27. Relling M.V., Lin J.S., Ayers G.D., et al. (1992): Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin. Pharmacol. Ther. 52, 643–658.

    PubMed  CAS  Google Scholar 

  28. Ereshefsky L., Saklad S.R., Watanabe M.D., et al. (1991): Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, and demographic variables. J. Clin. Psychopharmacol., 11, 296–301.

    Article  PubMed  CAS  Google Scholar 

  29. Bruguerolle B, Toumi M., Fraj F., et al. (1990): Influence of menstrual cycle on theophylline pharmacokinetics in asthmatics. Eur. J. Clin. Pharmacol., 39, 59–61.

    Article  PubMed  CAS  Google Scholar 

  30. Lane J.D., Steege J.F., Rupp S.L., et al. (1992): Menstrual cycle effects on caffeine elimination in the human female. Eur. J. Clin. Pharmacol., 43, 543–546.

    Article  PubMed  CAS  Google Scholar 

  31. Lobo J., Kack D., Kendall M.J. (1986): The intra- and inter-subject variability of nifedipine pharmacokinetics in young volunteers. Eur. J. Clin. Pharmacol., 30, 57–60.

    Article  PubMed  CAS  Google Scholar 

  32. Lemmens H.J.M., Burn A.G.L., Hennis P.J., et al. (1990): Influence of age on the pharmacokinetics of alfentanil. Clin. Pharmacokinet., 19, 416–422.

    Article  PubMed  CAS  Google Scholar 

  33. Sitar D., Duke P.C., Benthuysen J.L., et al. (1989): Aging and alfentanil disposition in healthy volunteers and surgical patients. Can. J. Anaesthesiol., 36, 149–154.

    Article  CAS  Google Scholar 

  34. Yee G.C., Lennon, T.P., Gmur D.J., et al. (1986): Age-dependent cyclosporine: pharmacokinetics in marrow transplant recipients. Clin. Pharmacol. Ther., 40, 438–443.

    PubMed  CAS  Google Scholar 

  35. Kahan B.D., Kramer W.G., Wideman C., et al. (1986): Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation, 41, 459–464.

    Article  PubMed  CAS  Google Scholar 

  36. Watkins P.B. (1994): Noninvasive tests of CYP3A enzymes. Pharmacogenetics, 4, 171–184.

    Article  PubMed  CAS  Google Scholar 

  37. Austin K.L., Mather L.E., Philpot C.R., et al. (1980): Intersubject and dose-related variability after intravenous administration of erythromycin. Br. J. Clin. Pharmacol., 10, 237–239.

    Google Scholar 

  38. Watkins P.B., Wrighton S.A., Maurel P., et al. (1985): Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. USA 82, 6310–6314.

    Article  PubMed  CAS  Google Scholar 

  39. Watkins P.B., Turgeon D.K., Saenger P., et al. (1992): Comparison of urinary 6-beta-cortisol and erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin. Pharmacol. Ther., 52, 265–273.

    PubMed  CAS  Google Scholar 

  40. Lew K.H., Ludwig E.A., Milad M.A., et al. (1993): Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther., 54, 402–414.

    PubMed  CAS  Google Scholar 

  41. Meffin P.J., Brooks P.N.M., Sallustio B.C. (1984): Alterations in prednisolone disposition as a result of time of administration, gender and dose. Br. J. Clin. Pharmacol., 17, 395–404.

    PubMed  CAS  Google Scholar 

  42. Hulst L.K., Fleishaker J.C., Peters G.R., et al. (1994): Effect of age and gender on tirilazad pharmacokinetics in humans. Clin. Pharmacol. Ther., 55, 378–384.

    PubMed  CAS  Google Scholar 

  43. Alvan G., Bechtel P., Iselius L., Gundert-Remy U. (1990): The hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol., 39, 533–537.

    Article  PubMed  CAS  Google Scholar 

  44. Brosen K., Gram L.F. (1986): Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur. J. Clin. Pharmacol., 36, 537–547.

    Article  Google Scholar 

  45. Gram L.F., Brosen K., Sindrup S., Skjelbo. (1995): Genetic and interethnic variability in drug metabolism: what are the clinical consequences? In: Alvan G., Balant L.P., Bechtel P.R., Boobis A.R., Gram L.F., Paintaud, G., Pithan K. (Eds) European Conference on Specificity and Variability in Drug Metabolism. Luxembourg, Office for Official Publications of the European Communities, pp. 235–245.

    Google Scholar 

  46. Wrighton S.A., Stevens J.C. (1992): The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol., 22, 1–21.

    Article  PubMed  CAS  Google Scholar 

  47. Leeman T.D., Transon C., Bonnabry P., et al. (1993): A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp. Clin. Res., 19, 189–195.

    Google Scholar 

  48. Rugstad H.E., Hundal O., Holme I., et al. (1986): Piroxicam and naproxen plasma concentrations in patients with osteoarthritis: relation to age, sex, efficacy and adverse events. Clin. Rheumatol., 5, 389–398.

    Article  PubMed  CAS  Google Scholar 

  49. Richardson C.J., Blocka K.L.N., Ross S.G., et al. (1985): Effects of age and sex on piroxicam disposition. Clin. Pharmacol. Ther., 37, 13–18.

    PubMed  CAS  Google Scholar 

  50. Miners J.O., Robson R.A., Birkett D.J. (1984): Gender and oral contraceptive steroids as determinants of drug glucuronidation: effects on clofibrinic acid elimination. Br. J. Clin. Pharmacol., 18, 240–243.

    PubMed  CAS  Google Scholar 

  51. Greenblatt D.J., Abernethy D.A., Matlis R., et al. (1984): Absorption and distribution of ibuprofen in the elderly. Arthritis Rheum., 27, 1066–1069.

    Article  PubMed  CAS  Google Scholar 

  52. Miners J.O., Attwood J., Birkett D.J. (1983): Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br. J. Clin. Pharmacol., 16, 503–509.

    PubMed  CAS  Google Scholar 

  53. Macdonald J.L., Herman R.J., Verbeek R.K. (1990): Sex-difference and the effects of smoking and oral contraceptive steroids on the kinetics of diflunisal. Eur. J. Clin. Pharmacol., 38, 175–179.

    PubMed  CAS  Google Scholar 

  54. Wedel M., Pieters J.E., Pikaar N.A., et al. (1991): Application of a three compartment model to a study of the effects of sex, alcohol dose and concentration, exercise and food consumption on the pharmacokinetics of ethanol in healthy volunteers. Alcohol, 26, 329–336.

    CAS  Google Scholar 

  55. Port R.E., Daniel B., Ding R.W. (1991): Relative importance of body surface area, sex, and age for 5-fluorouracil clearance. Oncology, 48, 277–281.

    Article  PubMed  CAS  Google Scholar 

  56. Milano G., Etienne M.C., Cassuto-Viguier E. (1992): Influence of sex and age on fluorouracil clearance. J. Clin. Oncol., 10, 1171–1175.

    PubMed  CAS  Google Scholar 

  57. Cockcroft D.W., Gault M.H. (1976): Prediction of creatinine clearance from serum creatinine. Nephron, 16, 31–41.

    Article  PubMed  CAS  Google Scholar 

  58. Gaudry S.E., Sitar D.S., Smyth D.D. (1993): Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. Clin. Pharmacol. Ther., 54, 23–27.

    PubMed  CAS  Google Scholar 

  59. Hildebrandt R., Weitzel H., Warnke K., Gundert-Remy U. (1993): Pharmacokinetics of fenoterol in pregnant and nonpregnant women. Eur. J. Clin. Pharmacol., 45, 275–277.

    Article  PubMed  CAS  Google Scholar 

  60. Hildebrandt R., Wagner B., Preiss-Nowtohour K., Gundert-Remy U. (1994): Fenoterol metabolism in man: sulphation versus glucuronidation. Xenobiotica, 24, 71–77.

    Article  PubMed  CAS  Google Scholar 

  61. Davis C.E., Leffingwell D.P. (1990): Empirical Bayes estimates of subgroup effects in clinical trials. Controlled Clin. Trials, 11, 37–42.

    Article  PubMed  CAS  Google Scholar 

  62. Yusuf S., Wittes J., Probstfield J., Tyroler H.A. (1990): Analysis and interpretation of treatment effects in subgroup of patients in randomized clinical trials. JAMA, 266, 93–98.

    Article  Google Scholar 

  63. Allgulander C., Nasman P. (1991): Regular hypnotic drug treatment in a sample of 32 679 Swedes. Association with somatic and mental health, inpatient psychiatric diagnoses and suicide, derived with automated record linkage. Psychosom. Med., 53, 101–108.

    PubMed  CAS  Google Scholar 

  64. Rosholm J.U., Hallas J., Gram L.F. (1993): Outpatient utilization of antidepressants: a prescription database analysis. J. Affect. Disord., 27, 21–28.

    Article  PubMed  CAS  Google Scholar 

  65. Schmucker D.L., Vesell E.S. (1993): Underrepresentation of women in clinical drug trials. Clin. Pharmacol. Ther., 54, 11–15.

    PubMed  CAS  Google Scholar 

  66. Elks M.L. (1993): The right to participate in research studies. J. Lab. Clin. Med., 122, 130–136.

    PubMed  CAS  Google Scholar 

  67. Von Bahr C., Ekblom M., Knoph L., Salmonsson T., Sjöberg P. (1995): Specificity and variability in drug metabolism: regulatory point of view. In: Alvan G., Balant L.P., Bechtel P.R., Boobis A.R., Gram L.F., Paintaud G., Pithan K. ({eEds}) European Conference on Specificity and Variability in Drug Metabolism. Luxembourg, Office for Official Publications of the European Communities, pp. 285–290.

    Google Scholar 

  68. Fisher B., Wolmark N., Rockette H., et al. (1988): Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J. Natl. Cancer Inst., 80, 21–29.

    Article  PubMed  CAS  Google Scholar 

  69. Merkatz R.B., Temple R., Sobel S., Feiden K., Kessler D.A., Working Group on Women in Clinical Trials (1993): Women in clinical trials of new drugs — a change in Food and Drug Administration policy. N. Engl. J. Med., 329, 292–296.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Center of Pharmacology and Toxicology, University of Göttingen, Robert-Koch-Strasse 40, D-37075, Göttingen, Germany

    C. H. Gleiter & U. Gundert-Remy

Authors
  1. C. H. Gleiter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. Gundert-Remy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gleiter, C.H., Gundert-Remy, U. Gender differences in pharmacokinetics. European Journal of Drug Metabolism and Pharmacokinetics 21, 123–128 (1996). https://doi.org/10.1007/BF03190260

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190260

Keywords

Search

Navigation